Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ying Lan, Nan Yang, Yirong Wang, Yan Yang, Min Xu & Qin He. (2023) Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 2093-2103.
Read now
Read now
Enrico de Nigris, Catrin Treharne, Nick Brighton, Ulf Holmgren, Andrew Walker & John Haughney. (2022) Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2987-3000.
Read now
Read now
Ying Lan, Nan Yang, Yirong Wang, Yujie Yang, Min Xu & Qin He. (2022) Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 609-619.
Read now
Read now
Arschang Valipour, Sergey Avdeev, Adam Barczyk, Valentina Bayer, Zvi Fridlender, Mariela Georgieva, Ondřej Kudela, Alexey Medvedchikov, Ramona Miron, Maria Sanzharovskaya, Virginija Šileikienė, Jurij Šorli, Marc Spielmanns & Zsuzsanna Szalai. (2021) Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 615-628.
Read now
Read now
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Bhavesh Lakhotia, Ronan Mahon, Florian S Gutzwiller, Andriy Danyliv, Ivan Nikolaev & Praveen Thokala. (2020) Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 787-797.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Krithika Rajagopalan, Lisa Bloudek, Jessica Marvel, Carole Dembek & Abhishek Kavati. (2018) Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3867-3877.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero-Acuña, Eduardo Márquez-Martín, Esther Quintana Gallego, Laura Carrasco-Hernández, Maria Abad Arranz & Francisco Ortega Ruiz. (2017) Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1867-1876.
Read now
Read now
Articles from other publishers (10)
Jia Liu, Xiaoning He & Jing Wu. (2022) Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. Applied Health Economics and Health Policy 20:5, pages 743-755.
Crossref
Crossref
Yinhua Gong, Chen Lin, Yifeng Jin & Rong Chen. (2022) The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal 2022, pages 1-12.
Crossref
Crossref
Marc Spielmanns, Sebastian Schildge, Jens Peter Diedrich & Arschang Valipour. (2022) Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment. Clinics and Practice 12:1, pages 46-56.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran & Beth Hahn. (2021) Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D. MacKnight & Beth Hahn. (2021) Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary Therapy 7:1, pages 203-219.
Crossref
Crossref
Shuli Qu, Xuedan You, Tianyi Liu, Lijiao Wang, Zheng Yin, Yanjun Liu, Chong Ye, Ting Yang, Mao Huang, Hongchao Li, Liwen Fang & Jinping Zheng. (2021) Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China. npj Primary Care Respiratory Medicine 31:1.
Crossref
Crossref
Wijdan H. Ramadan, Sarah Al Masri & John Rizk. (2019) Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. The Clinical Respiratory Journal 13:11, pages 663-673.
Crossref
Crossref
Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray & Richard H. Stanford. (2018) The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río & N. A. Risebrough. (2018) Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respiratory Research 19:1.
Crossref
Crossref
Margarita Capel, María Mareque, Carlos José Álvarez, Leandro Lindner & Itziar Oyagüez. (2018) Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clinical Drug Investigation 38:7, pages 611-620.
Crossref
Crossref